Adjuvant Pembrolizumab and Survival in Renal-Cell Carcinoma | NEJM

Adjuvant pembrolizumab was approved for patients with renal-cell carcinoma on the basis of improvements in disease-free survival observed in the KEYNOTE-564 trial. Data on overall survival are needed.
Research findings are summarized in a Quick Take video.
To see the full article, follow this link: nej.md/3TVLuKz
#oncology #cancerresearch #clinicaltrials #medicalresearch #nejm

[@adithyavikram7]

Few doubts is it effective on all types of renal cell carcinoma, racial difference,sex difference,age difference and what about its cost effectiveness in tropical countries.

[@nikhilera738]

But what about safety issues, does risk benefit favour the use of pembrolizumab?